Innovative Peptide Drug Conjugate (PDC) Technology to improve Cancer Treatments.
Our Technology
Phi’s PDCs target a biologically validated and widely expressed cancer antigen that remains under-explored – Chondroitin-Sulfate Proteoglycan-4 (CSPG4).
Our Programmes
CSPG4 is very difficult to target effectively using conventional antibody-based technologies. Multiple solid and liquid tumours are characterized by high CSPG4 expression levels.
Unlock the full potential of targeted therapies through Phi Pharma's proprietary Peptide Drug Conjugate (PDC) technology platform
Deep Hematology/Oncology Drug Development & Commercialization Experience to advance strategic goals in the development of our pipeline of PDCs across multiple cancer indications.
